Back in June, CMS proposed significant updates to its current TAVR policies. Three leading healthcare societies have now joined forces to share their own perspective on the potential updates. 

Long-term TAVR outcomes were comparable. When tracking 30-day data, however, researchers found that hospital readmission was much less common for patients treated with regional anesthesia or moderate sedation.

Cardiologists have always wanted a better way to identify heart patients in need of care early in their course of disease. Artificial intelligence may be the tool physicians have been waiting for. 

Treating asymptomatic patients with TAVR may cost more at first, but it appears to be a wise financial decision as time goes on.

The De Ritis ratio could be a new way to anticipate when TAVR patients may face certain short-term risks after treatment.

High-volume hospitals are often associated with better TAVR outcomes. The team behind this new study wanted to see if a similar trend was seen with FTR rates as well. 

The CALLY index, a biomarker that examines systemic inflammation, immune system activity and nutrition, could provide care teams with significant value.

Low-risk patients face comparable outcomes after TAVR and SAVR, researchers wrote, making it important to highlight even the smallest differences between these two approaches.